Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$1.04M-$1.04MN/M vs Q2 2024 EPS Diluted-$0.09-$0.09N/M vs Q2 2024 Operating Income-$1,745,511N/M Operating Cash Flowderived-$1,375,360N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end